Cargando…
Management of diabetes mellitus in patients with chronic kidney disease
Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469199/ https://www.ncbi.nlm.nih.gov/pubmed/28702221 http://dx.doi.org/10.1186/s40842-015-0001-9 |
_version_ | 1783243545877938176 |
---|---|
author | Hahr, Allison J. Molitch, Mark E. |
author_facet | Hahr, Allison J. Molitch, Mark E. |
author_sort | Hahr, Allison J. |
collection | PubMed |
description | Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c is approximately 7 % but this target is adjusted based on the needs of the patient. Diabetes control should be optimized for each individual patient, with measures to reduce diabetes-related complications and minimize adverse events. Overall care of diabetes necessitates attention to multiple aspects, including reducing the risk of cardiovascular disease, and often, multidisciplinary care is needed. |
format | Online Article Text |
id | pubmed-5469199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54691992017-07-12 Management of diabetes mellitus in patients with chronic kidney disease Hahr, Allison J. Molitch, Mark E. Clin Diabetes Endocrinol Review Article Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c is approximately 7 % but this target is adjusted based on the needs of the patient. Diabetes control should be optimized for each individual patient, with measures to reduce diabetes-related complications and minimize adverse events. Overall care of diabetes necessitates attention to multiple aspects, including reducing the risk of cardiovascular disease, and often, multidisciplinary care is needed. BioMed Central 2015-06-04 /pmc/articles/PMC5469199/ /pubmed/28702221 http://dx.doi.org/10.1186/s40842-015-0001-9 Text en © Hahr and Molitch; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Article Hahr, Allison J. Molitch, Mark E. Management of diabetes mellitus in patients with chronic kidney disease |
title | Management of diabetes mellitus in patients with chronic kidney disease |
title_full | Management of diabetes mellitus in patients with chronic kidney disease |
title_fullStr | Management of diabetes mellitus in patients with chronic kidney disease |
title_full_unstemmed | Management of diabetes mellitus in patients with chronic kidney disease |
title_short | Management of diabetes mellitus in patients with chronic kidney disease |
title_sort | management of diabetes mellitus in patients with chronic kidney disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469199/ https://www.ncbi.nlm.nih.gov/pubmed/28702221 http://dx.doi.org/10.1186/s40842-015-0001-9 |
work_keys_str_mv | AT hahrallisonj managementofdiabetesmellitusinpatientswithchronickidneydisease AT molitchmarke managementofdiabetesmellitusinpatientswithchronickidneydisease |